Abstract
Thirty secnidazole derivatives have been synthesized and evaluated for Helicobacter pylori (H. Pylori) urease inhibitory activities and anti-inflammatory activities. All of them were reported for the first time. Their chemical structures were characterized by 1H NMR, 13C NMR, MS, and elemental analysis. Compound 5a, 6c and 8c showed the most potent urease inhibitory activities and anti-inflammatory activities with IC50 values of 1.7 μM, 1.0 μM, 2.0 μM and inhibition of 62.60%, 59.54%, 71.76%, respectively. Docking simulation was performed to position compound 6c into the urease active site to determine the probable binding model. Compound 5a, 6c and 8c with potent inhibitory activity against H. pylori may be potential antibacterial agents.
Keywords: Urease inhibitors, Helicobacter pylori, secnidazole derivatives, salicyclic acid derivatives, anti-inflammatory activites, docking, antibacterial agent, urea hydrolase, gastroduodenal diseases, living organisms
Current Bioactive Compounds
Title: The Synthesis, Structure and Activity Evaluation of Secnidazole Derivatives as Helicobacter pylori Urease Inhibitors
Volume: 7 Issue: 4
Author(s): Xi-Shou Huang, Kai Liu, Yong Yin, Wan-Mei Li, Wei Ran, Man Duan, Li-Sheng Wang and Hai-Liang Zhu
Affiliation:
Keywords: Urease inhibitors, Helicobacter pylori, secnidazole derivatives, salicyclic acid derivatives, anti-inflammatory activites, docking, antibacterial agent, urea hydrolase, gastroduodenal diseases, living organisms
Abstract: Thirty secnidazole derivatives have been synthesized and evaluated for Helicobacter pylori (H. Pylori) urease inhibitory activities and anti-inflammatory activities. All of them were reported for the first time. Their chemical structures were characterized by 1H NMR, 13C NMR, MS, and elemental analysis. Compound 5a, 6c and 8c showed the most potent urease inhibitory activities and anti-inflammatory activities with IC50 values of 1.7 μM, 1.0 μM, 2.0 μM and inhibition of 62.60%, 59.54%, 71.76%, respectively. Docking simulation was performed to position compound 6c into the urease active site to determine the probable binding model. Compound 5a, 6c and 8c with potent inhibitory activity against H. pylori may be potential antibacterial agents.
Export Options
About this article
Cite this article as:
Huang Xi-Shou, Liu Kai, Yin Yong, Li Wan-Mei, Ran Wei, Duan Man, Wang Li-Sheng and Zhu Hai-Liang, The Synthesis, Structure and Activity Evaluation of Secnidazole Derivatives as Helicobacter pylori Urease Inhibitors, Current Bioactive Compounds 2011; 7 (4) . https://dx.doi.org/10.2174/157340711798375868
DOI https://dx.doi.org/10.2174/157340711798375868 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overview of the Molecular Bases of Resistance to Chemotherapy in Liver and Gastrointestinal Tumours
Current Molecular Medicine TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy
Current Pharmaceutical Biotechnology Recent Developments and Applications of Derivative Spectrophotometry in Pharmaceutical Analysis
Current Pharmaceutical Analysis Bioproducts from Seaweeds: A Review with Special Focus on the Iberian Peninsula
Current Organic Chemistry Medicinal Plants for the Prevention and Treatment of Bacterial Infections
Current Pharmaceutical Design Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Current Hypertension Reviews A Validated 2D-LC-UV Method for Simultaneous Determination of Imatinib and N-desmethylimatinib in Plasma and its Clinical Application for Therapeutic Drug Monitoring with GIST Patients
Current Pharmaceutical Analysis Bioavailability Challenges Associated with Development of Saponins As Therapeutic and Chemopreventive Agents
Current Drug Targets Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism Give Boron a Chance: Boron Containing Compounds Reach Ionotropic and Metabotropic Transmembrane Receptors
Mini-Reviews in Medicinal Chemistry Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry DNA Methylation: An Epigenetic Insight into Type 2 Diabetes Mellitus
Current Pharmaceutical Design Safety and Proof-of-Concept Efficacy of Inhaled Drug Loaded Nano- and Immunonanoparticles in a c-Raf Transgenic Lung Cancer Model
Current Cancer Drug Targets Editorial [Hot topic: Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement. Part II (Executive Editors: Calogero Caruso, Thea Magrone and Emilio Jirilllo)]
Current Pharmaceutical Design Toxicophoric and Metabolic In Silico Evaluation of Benzimidazole and Phenylbenzamide Derivatives with Potential Application as Anticancer Agents
Drug Metabolism Letters Gastroretentive Drug Delivery System of Metoclopramide Hydrochloride: Formulation and In vitro Evaluation
Current Drug Delivery Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy Investigation of Novel Chemical Inhibitors of Human Lysosomal Acid Lipase: Virtual Screening and Molecular Docking Studies
Combinatorial Chemistry & High Throughput Screening